Meeting
2017 Genitourinary Cancers Symposium
A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.
Authors
Steven Yu
University of Southern California, Los Angeles, CA
Steven Yu , Kanthi Athreya , Stephen V. Liu , Andrew V. Schally , Susan G. Groshen , Denice D Tsao-Wei , David I. Quinn , Tanya B. Dorff , Shigang Xiong , Jacek Pinski , Jurgen Engel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01240629
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 210)
DOI
10.1200/JCO.2017.35.6_suppl.210
Abstract #
210
Poster Bd #
H12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
First Author: David James VanderWeele
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
First Author: Yu-Wei Chen
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2022 ASCO Annual Meeting
A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
First Author: David R Wise